Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.80 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640309 | 0.86 | PTGS2 (0.65) | PTGS2MEN1MAPTKMT2A | |
| SCHEMBL28294494 | 0.85 | PTGS2 (1.00) | PTGS2CHRNA7PTGS1MEN1MAPT | |
| SCHEMBL28292893 | 0.85 | PTGS2 (1.00) | PTGS2CHRNA7PTGS1MEN1MAPT | |
| SCHEMBL28292993 | 0.83 | PTGS2 (1.00) | PTGS2CHRNA7MEN1MAPTKMT2A | |
| SCHEMBL28872997 | 0.83 | PTGS2 (1.00) | PTGS2CHRNA7PTGS1MEN1MAPT | |
| SCHEMBL28292886 | 0.83 | PTGS2 (1.00) | PTGS2CHRNA7MEN1MAPTKMT2A | |
| SCHEMBL28292890 | 0.83 | PTGS2 (1.00) | PTGS2CHRNA7MEN1MAPTKMT2A | |
| SCHEMBL28872794 | 0.83 | PTGS2 (1.00) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL28294500 | 0.81 | PTGS2 (1.00) | PTGS2CHRNA7PTGS1MEN1MAPT | |
| SCHEMBL28292903 | 0.81 | PTGS2 (1.00) | PTGS2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | PTGS2 47/4885CA1 7/4885CA2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.